IMV Inc IMVIF

Reality Check

[TexasTea20]

Some additional thoughts on a home -boundCovid Saturday afternoon as I think more about the continued bungling of timelines, super-slow clinical progress, unreliable messaging and IMV's valuation / share price.

Before I say more I want to be clear that if I didn't think I could make some money on this play I would not have re-upped after the deserved latest beat-down coming out of the March 17 earnings call. Its all a question of timelines and realzing full potential that has me wanting to point out a few things.

The reality. 

-IMV is a two decades old company
-IMV only has a single product (DPX-Survivin) in active Clinical trials after two decades with   what is  positioned as aplatform technolgy
-It has 4 people in the C-Suite including a CEO who sits on the BOD.
-IMV has 7n VP's last time I checked for this one product company in PII trials
-In my opinion IMV is undervalued at least 3-5X to its well-managed peers at a similar point of   development

I have concerns that some key shareholders may see a Class Action Opportunity related to what I suggested in the first sentence. BOD is asleep at the switch.

I have further concerns that IMV will announce a weak deal with Merck not reflecting the potential in the DLBCL indication or the platform overall. This is mostly just worry however, but with good reason I beleive.

In differnet hands I believe this technolgy platform would have been bought and sold for considerable valuation some time ago. We have a time value of money and developing technology obsolence problem considering the excruciatingly slow progress.

Let me try an analogy. Think of DPX as a basketball lying at center court (DPX). What the basketball can do is entirely dependent on who picks it up, their skills, competence, drive etc...
The DPX ball has unfortunately been picked up by a minor league group of players and not an NBA level group of players. You can still make money in the minor leagues with that same ball but thats about it. 

Qwerty, making excuses for IMV, said Biotech is hard and it is. But its much harder for some than others.

Good luck. We are going to need it if we want to get max value from this mis-managed originally promising platform technolgy. Again, despite personally sitting on a significant loss right now I think we'll make some money but not what we should.